SCHEMBL319757

SCHEMBL319757

Fc1c(Br)ccc(OCc2ccccc2)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.44
HTR1A P08908 2/20 0.43
DRD2 P14416 1/20 0.43
MAOB P27338 1/20 0.42
LIPE Q05469 1/20 0.42
FOLH1 Q04609 1/20 0.42
SLC6A4 P31645 2/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
CCR5 P51681 1/20 0.41
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
LTA4H P09960 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30782654 1.00 KDM1A (0.47) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL8619299 0.94 KDM1A (0.43) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL8613438 0.94 KDM1A (0.43) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL26604918 0.91 SMN1; SMN2 (0.44) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL8613441 0.89 KDM1A (0.40) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL31166800 0.86 KDM1A (0.44) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL2782931 0.86 TDP1 (0.55) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL30032144 0.86 TDP1 (0.55) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL23887259 0.85 MAPK14 (0.44) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1
SCHEMBL31285234 0.85 KDM1A (0.47) KDM1ARAB9ASMN1; SMN2TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117501826-A Electronic component comprising a plurality of cells arranged in a three-dimensional array of cells and method for producing such an electronic device 默克专利有限公司 2024-02-02 CN disclosed
US-20230057166-A1 PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE GENENTECH INC (US) 2023-02-23 US disclosed
WO-2022258563-A1 ELECTRONIC ELEMENT COMPRISING A PLURALITY OF CELLS ARRANGED IN A THREE DIMENSIONAL ARRAY OF CELLS AND METHOD FOR PRODUCING SUCH AN ELECTRONIC DEVICE MERCK PATENT GMBH (DE) 2022-12-15 WO disclosed
EP-4102571-A1 ELECTRONIC ELEMENT COMPRISING A PLURALITY OF CELLS ARRANGED IN A THREE DIMENSIONAL ARRAY OF CELLS AND METHOD FOR PRODUCING SUCH AN ELECTRONIC DEVICE Merck Patent GmbH (DE) 2022-12-14 EP disclosed
US-11427598-B2 Spiro-cyclic amine derivatives as S1P modulators AbbVie Deutschland GmbH & Co. KG (DE) 2022-08-30 US disclosed
EP-3849664-A1 PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE Genentech, Inc. (US) 2021-07-21 EP disclosed
US-20210130364-A1 SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS ABBVIE B.V. (NL) 2021-05-06 US disclosed
CN-112739420-A Phenoxy-pyridyl-pyrimidine compounds and methods of use 基因泰克公司 2021-04-30 CN disclosed
US-10807991-B2 Spiro-cyclic amine derivatives as S1P modulators ABBVIE B.V. (NL) 2020-10-20 US disclosed
WO-2020056089-A1 PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE GENENTECH, INC. (US) 2020-03-19 WO disclosed
WO-2012004378-A1 SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2012-01-12 WO disclosed
WO-2012004378-A1 SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2012-01-12 WO disclosed
EP-2271617-B1 SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS GLAXO GROUP LTD (GB) 2011-11-30 EP disclosed
US-20110240919-A1 FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2011-10-06 US disclosed
US-20110240919-A1 FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2011-10-06 US disclosed
US-7956083-B2 Compounds GLAXO GROUP LIMITED (GB) 2011-06-07 US disclosed
EP-2271617-A1 SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS Glaxo Group Limited (GB) 2011-01-12 EP disclosed
US-20100324106-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2010-12-23 US disclosed
WO-2009103710-A1 SUBSTITUTED 4-HYDROXY-N- (4-HYDROXYPHENYL) INDOLES AS ESTROGENIC AGENTS GLAXO GROUP LIMITED (GB) 2009-08-27 WO disclosed
WO-1994010179-A1 ARYLBORON ACIDS AS INTERMEDIATES IN THE PRODUCTION OF COMPONENTS OF LIQUID-CRYSTAL MIXTURES HOECHST AKTIENGESELLSCHAFT (DE) 1994-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11427598-B2 Spiro-cyclic amine derivatives as S1P modulators S1PR1, S1PR3, S1PR2 KDM1A 3503/4885RAB9A 1798/4885SMN1; SMN2 3210/4885
US-20110240919-A1 FIVE-RING COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE NCAPD3, CCND3, ZKSCAN2 KDM1A 885/4885RAB9A 1980/4885SMN1; SMN2 3764/4885
US-10807991-B2 Spiro-cyclic amine derivatives as S1P modulators S1PR1, S1PR3, S1PR2 KDM1A 3503/4885RAB9A 1798/4885SMN1; SMN2 3210/4885
US-20230057166-A1 PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE XBP1, ERN1, ESR2 KDM1A 2617/4885RAB9A 4071/4885SMN1; SMN2 1892/4885
US-20210130364-A1 SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS S1PR1, S1PR3, S1PR2 KDM1A 3503/4885RAB9A 1798/4885SMN1; SMN2 3210/4885
US-20100324106-A1 COMPOUNDS ESR2, GPER1, ESR1 KDM1A 2532/4885RAB9A 3068/4885SMN1; SMN2 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.